SCTXNasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Scribe Therapeutics, Inc.

Scribe Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing precision-engineered CRISPR genetic medicines. Its wholly owned pipeline focuses on cardiometabolic diseases, including atherosclerotic cardiovascular disease, while collaborations with Eli Lilly and Sanofi apply its ELXR and XE technologies to additional therapeutic areas.

Kysy yhtiöstä

Liiketoiminta

Osuus liikevaihdosta
Wholly owned therapeutic pipeline0 %

Genetic medicine programs targeting cardiometabolic diseases such as ASCVD.

CRISPR technology platforms35 %

ELXR and XE platforms designed to support precision gene-editing applications.

Collaborative research programs65 %

Partner-funded development programs with Eli Lilly, Sanofi, and other potential collaborators.

Asiakkaat

Scribe's current commercial counterparties are biopharmaceutical collaborators, including Eli Lilly and Sanofi, which license or fund applications of its gene-editing technologies in selected therapeutic areas. These partners provide research funding, upfront payments, milestone opportunities, and potential royalties while contributing development and commercialization capabilities. Future end-market customers would include healthcare providers, payors, and patients if Scribe's product candidates receive regulatory approval.

Biopharmaceutical collaborators

License Scribe's CRISPR platforms and fund therapeutic development in selected disease areas.

Healthcare providers

Would administer or prescribe approved genetic medicines for cardiometabolic and other diseases.

Commercial and government payors

Would reimburse approved therapies and influence patient access through coverage decisions.

Patients

Would receive durable, potentially single-administration treatments for serious diseases.

Strategia

Scribe's strategy is to advance its wholly owned cardiometabolic pipeline while using its CRISPR platforms in collaborations that broaden therapeutic reach and provide non-dilutive funding. Near-term development priorities include progressing STX-1150, advancing additional preclinical and clinical programs, and building manufacturing, clinical, intellectual-property, and public-company capabilities. Collaborations with Eli Lilly and Sanofi are intended to validate platform versatility and share development and commercialization requirements.

Advance the cardiometabolic pipelineLyhyt aikaväli

Clinical progress is required to convert the technology platform into proprietary medicines.

Expand platform partnershipsKeskipitkä aikaväli

Collaborations extend applications of ELXR and XE while sharing development and commercialization resources.

Build development and commercialization infrastructureKeskipitkä aikaväli

Manufacturing, clinical, regulatory, and commercial capabilities are necessary for eventual product approval and launch.

Maantiede

Scribe Therapeutics is headquartered and organized in the United States, where its research, corporate, clinical-development, and public-company activities are managed. The company does not disclose country-level revenue or a regional revenue mix in the provided materials. Its collaborations and future clinical programs may require international regulatory, trial, manufacturing, and commercialization activities.

Riskit

Scribe remains dependent on successful research, preclinical and clinical development, regulatory approval, and eventual market access because it has no approved products or product sales. Its collaboration-based revenue model exposes it to partner decisions on funding, trial execution, and commercialization, while the capital-intensive pipeline creates ongoing financing and dilution risk. Competition from established gene-editing and pharmaceutical companies, intellectual-property challenges, manufacturing constraints, and difficulty recruiting specialized personnel could delay or prevent commercialization.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Funding and dilution risk1Clinical-stage development failure2Collaboration dependence3Competitive pressure4Market access and reimbursement5Key personnel dependence6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Funding and dilution riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company has significant operating losses and negative operating cash flow while development requires substantial capital.

    KohdistuuResearchClinical developmentManufacturingPublic-company costs
  2. Clinical-stage development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Safety, efficacy, enrollment, manufacturing, or regulatory problems could prevent approval of product candidates.

    Kohdistuu: STX-1150 and other preclinical or clinical programs

  3. Collaboration dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Partners may delay, reduce, or terminate programs and control resources dedicated to development and commercialization.

    KohdistuuEli LillySanofiFuture biopharmaceutical partners
  4. Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Large pharmaceutical and biotechnology companies may have greater development, regulatory, manufacturing, and marketing resources.

    Kohdistuu: Gene editing and cardiometabolic therapeutic markets

  5. Market access and reimbursementVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Approved therapies may face restrictive coverage, inadequate reimbursement, or limited provider and patient adoption.

    Kohdistuu: Future commercialized genetic medicines

  6. Key personnel dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Loss of technical, scientific, or management personnel could delay programs and weaken execution.

    KohdistuuResearchClinicalCorporate operations
Kysy Clarifolta: Scribe Therapeutics, Inc.

Kirjanpito

Harkinnanvaraiset erät
Collaboration and license revenue recognition

Upfront, milestone, contingent, FTE, and reimbursement payments may be recognized at different times based on performance obligations and reversal constraints.

Vaikutus: Revenue can fluctuate substantially between reporting periods without corresponding product sales.

Milestone probability assessment

Milestone consideration is included in transaction price only when achievement is probable and a significant reversal is unlikely.

Vaikutus: Clinical and regulatory progress can change the timing of reported collaboration revenue.

Convertible note fair value

The Lilly convertible note is remeasured using assumptions about expected conversion.

Vaikutus: Changes in valuation create non-operating earnings volatility.

Research and development cost recognition

Internal and external R&D costs are expensed as incurred, while advance payments are deferred until goods or services are received.

Vaikutus: Timing of vendor delivery and clinical services affects reported operating expenses.

Deferred tax asset valuation allowance

Net operating losses and other tax attributes are offset by a full valuation allowance because realization is uncertain.

Vaikutus: Tax benefits are generally not recognized until future taxable income becomes more probable.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Crispr Therapeutics AG

CRSP · Biological Products, (No Diagnostic Substances)

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

Editas Medicine, Inc.

EDIT · Biological Products, (No Diagnostic Substances)

Lexeo Therapeutics, Inc.

LXEO · Biological Products, (No Diagnostic Substances)

Sarepta Therapeutics, Inc.

SRPT · Pharmaceutical Preparations

Intellia Therapeutics, Inc.

NTLA · In Vitro & In Vivo Diagnostic Substances

Päivitetty: 24.9.2026